Wong Chit Wai
Department of Medicine and Geriatrics, Caritas Medical Centre, Hong Kong, China.
Drugs Aging. 2016 Jul;33(7):451-60. doi: 10.1007/s40266-016-0372-3.
Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease. This article provides evidence-based recommendations to address the issues regarding the use of cholinesterase inhibitors and memantine in clinical practice. It includes their efficacy, timing, assessment, use in institutionalized patients, combined use, and use in other dementia types. However, most of the studies are of short duration (<1 year) and are mainly focused on cognitive and global improvement, whereas the practical issue of their use in daily practice such as optimal duration of treatment, long-term efficacy and delaying institutionalization are limited.
胆碱酯酶抑制剂和美金刚是仅有的两类被批准用于治疗阿尔茨海默病所致痴呆的药物。本文提供基于证据的建议，以解决临床实践中使用胆碱酯酶抑制剂和美金刚的相关问题。内容包括它们的疗效、用药时机、评估、在机构化患者中的使用、联合使用以及在其他类型痴呆中的使用。然而，大多数研究持续时间较短（<1年），且主要关注认知和整体改善情况，而它们在日常实践中的实际问题，如最佳治疗持续时间、长期疗效和延迟机构化等方面的研究有限。
